Genocea Biosciences Inc. Daily Stock Analysis

Daily Stock Analysis, GNCA, Genocea Biosciences Inc, priceseries

Genocea Biosciences Inc. Daily Stock Analysis
Stock Information
Open
1.10
Close
1.01
High
1.12
Low
0.99
Previous Close
1.08
Daily Price Gain
-0.07
YTD High
1.28
YTD High Date
Jan 4, 2022
YTD Low
0.85
YTD Low Date
Jan 24, 2022
YTD Price Change
-0.19
YTD Gain
-15.83%
52 Week High
3.32
52 Week High Date
Mar 22, 2021
52 Week Low
0.85
52 Week Low Date
Jan 24, 2022
52 Week Price Change
-1.63
52 Week Gain
-61.74%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jul 21. 2017
40.40
Jul 31. 2017
45.74
6 Trading Days
13.22%
Link
LONG
Aug 24. 2017
34.16
Sep 14. 2017
40.07
14 Trading Days
17.30%
Link
LONG
Mar 5. 2018
8.24
Mar 20. 2018
8.92
11 Trading Days
8.30%
Link
LONG
Sep 21. 2018
4.40
Oct 10. 2018
6.19
13 Trading Days
40.64%
Link
LONG
Jan 4. 2019
3.76
Jan 22. 2019
4.55
11 Trading Days
21.12%
Link
LONG
Feb 21. 2019
4.27
Mar 11. 2019
6.08
12 Trading Days
42.23%
Link
LONG
Apr 3. 2019
5.04
Apr 16. 2019
5.52
9 Trading Days
9.59%
Link
LONG
Mar 5. 2020
2.05
Mar 9. 2020
2.17
2 Trading Days
5.61%
Link
LONG
May 20. 2020
2.51
May 27. 2020
2.65
4 Trading Days
5.48%
Link
LONG
Jul 17. 2020
2.12
Jul 30. 2020
3.80
9 Trading Days
79.37%
Link
LONG
Oct 2. 2020
2.32
Oct 20. 2020
2.45
12 Trading Days
5.43%
Link
LONG
Dec 15. 2020
2.18
Dec 28. 2020
2.35
8 Trading Days
7.82%
Link
LONG
Dec 22. 2021
1.04
Jan 4. 2022
1.17
8 Trading Days
12.04%
Link
Company Information
Stock Symbol
GNCA
Exchange
NasdaqGM
Company URL
http://www.genocea.com
Company Phone
617-876-8191
CEO
Chip Clark
Headquarters
Massachusetts
Business Address
100 ACORN PARK DRIVE, CAMBRIDGE, MA 02140
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001457612
About

Genocea Biosciences is a biopharmaceutical company developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. The company uses its proprietary ATLAS™ antigen identification platform to build a pipeline of immunotherapies that currently includes GEN-003, an immunotherapy for genital herpes, and GEN-009, its first neoantigen cancer vaccine, for which an Investigational New Drug application filing is expected by the end of 2017. Genocea Biosciences was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

Description

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel vaccines and immunotherapies to treat infectious diseases. The company uses its proprietary discovery platform AnTigen Lead Acquisition System to design vaccines and immunotherapies that act through T cell immune responses. Its lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase 2 trial for the treatment of genital herpes infections. The company is also developing GEN-009, which is in pre-clinical stage for the treatment of immuno-oncology-neoantigen; and GEN-007 that is in research stage for the treatment of Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading